For years, the promise of mesenchymal stem cell (MSC) therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for commercial use, pricing for advanced cell therapies has often reached six figures, limiting access to a relatively small segment of patients and healthcare systems.
China’s first approved MSC therapy is challenging that assumption. Ruibosheng (amimestrocel injection), developed by Platinum Life Excellence Biotech, has entered the Chinese market at a price point that is a fraction of comparable cell therapies globally, highlighting how manufacturing innovation and scale may reshape the economics of regenerative medicine.
The National Medical Products Administration (NMPA) granted conditional approval to Ruibosheng on January 2, 2025, making it the first MSC-based cell therapy approved for market in China. The therapy was cleared for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) with predominant gastrointestinal involvement in patients aged 14 and older. Since receiving regulatory approval, Ruibosheng has progressed into commercial distribution and clinical adoption across Chinese hospitals. [Read more…]
